Combination therapy doubles one-year survival in pancreatic cancer trial

Combination therapy doubles one-year survival in pancreatic cancer trial Findings from the randomized trial suggest that modulating the tumour microenvironment alongside chemotherapy may offer a new strategy for improving outcomes in pancreatic cancer https://www.drugdiscoverynews.com/combination-therapy-doubles-one-year-survival-in-pancreatic-cancer-trial-17121?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9RiEgzqG9BeKuO8WgnmSKpSqzPzTpSI9AbY17AuDEDKdDSUrIjlVCO8YgrLjYA3YPQMpNYgKswuehIRq3e_fQVVk1tNA&_hsmi=416164333&utm_content=416164333&utm_source=hs_email A drug developed at Northwestern University has shown a promising survival advantage in patients with metastatic pancreatic cancer, a disease that remains among the deadliest solid tumours and is projected to become the second leading cause of cancer-related deaths in the US within the next decade.